IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences (NASDAQ: IDYA) announced that on Oct 30, 2025 its Compensation Committee granted non-qualified stock options for an aggregate of 73,500 shares to two newly hired employees as inducement awards under the company's 2023 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The options carry an exercise price of $31.60 per share (the closing price on the grant date), a 10-year term, and vest over four years (25% at the first anniversary of vesting commencement and the remaining 75% in equal monthly installments over the following three years), subject to continued service.
IDEAYA Biosciences (NASDAQ: IDYA) ha annunciato che il 30 ottobre 2025 il suo Comitato di Compensazione ha concesso stock option non qualificate per un totale di 73.500 azioni a due dipendenti appena assunti come premi di incentivazione ai sensi del Piano di Induzione 2023 della società, in conformità alla Nasdaq Listing Rule 5635(c)(4).
Le opzioni hanno un prezzo di esercizio di $31,60 per azione (il prezzo di chiusura nel giorno di concessione), una durata di 10 anni e maturano nel corso di quattro anni (il 25% al primo anniversario dell'inizio della maturazione e il restante 75% in rate mensili uguali nei tre anni successivi), soggette a continuato servizio.
IDEAYA Biosciences (NASDAQ: IDYA) anunció que el 30 de octubre de 2025 su Comité de Compensación otorgó opciones sobre acciones no calificadas por un total de 73,500 acciones a dos empleados recién contratados como premios de inducción bajo el Piano de Inducción 2023 de la empresa, de acuerdo con la Regla 5635(c)(4) de Nasdaq Listing.
Las opciones tienen un precio de ejercicio de $31.60 por acción (el precio de cierre en la fecha de concesión), un plazo de 10 años y se consolidarán durante cuatro años (el 25% en el primer aniversario del inicio de la consolidación y el 75% restante en cuotas mensuales iguales durante los tres años siguientes), sujeto a la continuidad del servicio.
IDEAYA Biosciences (NASDAQ: IDYA)는 2025년 10월 30일에 보상위원회가 회사의 2023 Inducement Plan에 따라 신임 직원 2명에게 총 73,500주의 비자격 스톡옵션을 inducement award로 부여했다고 발표했습니다. Nasdaq Listing Rule 5635(c)(4)에 따라.
옵션은 주당 행사가 $31.60의 행사가를 가지며(부여일의 종가), 10년의 만료기간, 4년에 걸쳐 가속 vesting되며(처음 기준 1주년에서 25%, 이후 남은 75%를 이후 3년간 매월 균등 분할 vesting), 지속적인 서비스가 조건입니다.
IDEAYA Biosciences (NASDAQ: IDYA) a annoncé que le 30 octobre 2025, son Comité de rémunération a accordé des options d’achat d’actions non qualifiées pour un total de 73 500 actions à deux nouveaux employés en tant que primes d’induction dans le cadre du Piano d’Induction 2023 de l’entreprise, conformément à la Nasdaq Listing Rule 5635(c)(4).
Les options ont un prix d’exercice de 31,60 $ par action (le cours de clôture à la date d’attribution), une durée de 10 ans et vistent sur quatre ans (25% au premier anniversaire du début du vesting et les 75% restants en versements mensuels égaux au cours des trois années suivantes), sous réserve de la poursistance du service.
IDEAYA Biosciences (NASDAQ: IDYA) gab bekannt, dass am 30. Oktober 2025 ihr Vergütungsausschuss nicht qualifizierte Aktienoptionen in insgesamt 73.500 Aktien an zwei neu eingestellte Mitarbeiter als Anreizpreise gemäß dem 2023 Inducement Plan des Unternehmens gemäß Nasdaq Listing Rule 5635(c)(4) gewährt hat.
Die Optionen haben einen Ausübungspreis von 31,60 $ pro Aktie (der Schlusskurs am Gewährungstag), eine Laufzeit von 10 Jahren und vesten über vier Jahre (25% beim ersten Jahr der Vesting-Beginn und die verbleibenden 75% in gleichen monatlichen Raten über die folgenden drei Jahre), vorbehaltlich fortgesetzten Dienstes.
IDEAYA Biosciences (NASDAQ: IDYA) أعلنت لجنة التعويضات لديها أنه في 30 أكتوبر 2025 منحت لجنة الميزانية خيارات أسهم غير مؤهلة بإجمالي 73,500 سهمًا لموظفين تم توظيفهما حديثاً كجوائز تحفيزية وفقاً لـ خطة التحفيز لعام 2023 للشركة وبما يتوافق مع قاعدة إدراج ناسداك 5635(c)(4).
تكون الخيارات بـ سعر ممارسة قدره 31.60 دولاراً للسهم (سعر الإغلاق في يوم المنح)، ومدة عشر سنوات، وتكتسب حقوقها خلال أربعة أعوام (25% في الذكرى الأولى لبداية الاستحقاق و75% المتبقية على أقساط شهرية متساوية خلال السنوات الثلاث التالية)، بشرط الاستمرار في الخدمة.
- None.
- None.
The 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of IDEAYA, or following a bona fide period of non-employment, as an inducement material to such individuals' entering into employment with IDEAYA, pursuant to Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.
Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski, Ph.D.
Chief Financial Officer
investor@ideayabio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302600601.html
SOURCE IDEAYA Biosciences, Inc.
FAQ
What did IDEAYA (IDYA) grant on October 30, 2025?
What is the exercise price and term of the IDYA inducement stock options?
How do the IDEAYA inducement options vest for new hires?
Under which plan were the IDYA inducement awards granted?
Why did IDEAYA use the 2023 Inducement Plan for these hires?
